However, SGLT2 inhibitors are not currently approved for primary prevention of cardiorenal comorbidities in T2D; additional evidence on outcomes in this setting may help us to explore the full potential of these agents. The gene discussed is SLC5A2; the disease is type 2 diabetes mellitus.